Browsing Tag
Camzyos
2 posts
Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Bristol Myers Squibb’s Camzyos cleared a key adolescent Phase 3 hurdle in oHCM. Read what the SCOUT-HCM data could mean for growth and competition.
FDA approves Cytokinetics’ MYQORZO for obstructive HCM after SEQUOIA-HCM trial success
FDA approves Cytokinetics’ aficamten for obstructive HCM. Find out what this means for cardiologists, patients, and rival Camzyos as MYQORZO prepares to launch.